SAN FRANCISCO–(BUSINESS WIRE)–The AI Conference, the leading conference for applied AI, has announced a full agenda of sessions with AI builders from Anthropic, crewAI, Google, Modular, NVIDIA, Ollama, OpenAI, Warp, and more that address both the business and technical perspectives of building AI systems and the constraints of deploying them at scale. The event program fosters a lively interdisciplinary dialogue the industry needs to move AI from vision into production. “A lot of AI conferenc
Month: September 2026
DALLAS–(BUSINESS WIRE)–CBRE Group, Inc. (NYSE: CBRE) will release its third quarter 2026 financial results at approximately 6:55 a.m. Eastern time on Thursday, October 22, 2026. Management will hold a conference call to discuss these results at 8:30 a.m. Eastern time on that same day (Thursday, October 22, 2026). The event will be webcast live and accessible through the Investor Relations section of the company’s website at www.cbre.com, along with a supplemental slide presentation, which is
WILMINGTON, Ohio–(BUSINESS WIRE)–Air Transport Services Group, Inc. (“ATSG” or “the Company”), a leading provider of aircraft leasing, air transportation, and aviation support solutions, today announced that it has entered into an agreement to sell Omni Air International (“Omni”), a provider of passenger ACMI and charter services, to OAI Holdings, LLC (“OAI”), a private company whose management team brings deep expertise in aviation. Financial terms of the transaction were not disclosed. Foun
Manchester, 28 September 2026.- Virtualware (EPA: ALVIR), a European pioneer in 3D-driven industrial software listed on Euronext Growth Paris, has completed the acquisition of 100% of Virtalis Holding, the Manchester-based virtual reality and RT3D visualization software company.
The acquisition more than doubles the company’s scale, with pro forma revenue increasing from €4.32 million to €10 million based on projected 2026 results.
The combined group creates one of the largest European providers of immersive visualization and digital twin technology for industry, nuclear, critical infrastructure and defence.
“This acquisition marks a significant milestone for Virtualware, not only because of its scale, but also because it strengthens our product portfolio and expands our industrial customer base,” said Unai Extremo, CEO and founder of Virtualware.
Virtalis, founded in 2003 and headquartered in Manchester, specializes in virtual reality and RT3D visualization software. Its technology is used by BAE Systems, Blue Origin, Lam Research, Seaspan, Subsea 7, Vestas, Thales, Lockheed Martin and Ford.
The acquisition further strengthens Virtualware’s international footprint, rising its revenue generated outside Spain from 54% to 78%. The United Kingdom becomes the largest market, accounting for 37.7% of the proforma combined group’s aggregate revenue.
The acquisition follows Virtualware’s track record of inorganic growth. In October 2024 it acquired Swedish company Simumatik, a specialist in emulation and digital twin technology.
Shareholders approved the transaction at the Extraordinary General Meeting held in Basauri on 21 September 2026. The acquisition combines a fixed payment of 5 million euros on completion plus a variable component linked to Virtalis’s operating results in 2026 and 2027, funded through commercial debt.
LKS Corporate Finance served as Lead Financial Advisor to Virtualware on its acquisition of Virtalis, providing comprehensive financial advisory services, including valuation, transaction structuring, negotiations and deal execution and Geldars LLP as the legal advisor.
“We are proud to have supported Virtualware in the execution of a highly strategic acquisition that strengthens its international footprint and reinforces its leadership in industrial software.” Mariano Colmenar, Head of LKS Corporate Finance.
The acquisition was structured through a financial syndicate backed by Banco Bilbao Vizcaya Argentaria (BBVA), the Instituto Vasco de Finanzas (IVF, the Basque Government’s public financial entity), Cofides, and Elkargi.
—
Founded in 2004, Virtualware is one of the leading companies in enterprise software based on immersive and real-time 3D technologies for industrial and educational environments.
Virtualware is headquartered in Bilbao, Spain, with subsidiaries in the United Kingdom, Canada, the United States, and Sweden.
Press and investors contacts
Aida Otaola: aotaola@virtualwareco.com
Investor Relations: ir@virtualwareco.com
Safe Harbor
This document is only provided for information purposes and does not constitute, nor should it be interpreted as, an offer to sell or exchange or acquire, or an invitation for offers to buy securities issued by any of the aforementioned companies. Any decision to buy or invest in securities in relation to a specific issue must be made solely and exclusively on the basis of the information set out in the pertinent prospectus filed by the company in relation to such specific issue. No one who becomes aware of the information contained in this report should regard it as definitive, because it is subject to changes and modifications.
This document contains or may contain forward looking statements regarding intentions, expectations or projections of Virtualware 2007, S.A. (“Virtualware” or the “Company”) or of its management on the date thereof, that refer to or incorporate various assumptions and projections, including projections about the future earnings of the business. The statements contained herein are based on our current projections, but the actual results may be substantially modified in the future by various risks and other factors that may cause the results or final decisions to differ from such intentions, projections or estimates. These factors include, without limitation, (1) the market situation, macroeconomic factors, regulatory, political or government guidelines, (2) domestic and international stock market movements, exchange rates and interest rates, (3) competitive pressures, (4) technological changes, (5) alterations in the financial situation, creditworthiness or solvency of our customers, debtors or counterparts. These factors could cause or result in actual events differing from the information and intentions stated, projected or forecast in this document or in other past or future documents. Virtualware does not undertake to publicly revise the contents of this or any other document, either if the events are not as described herein, or if such events lead to changes in the information contained in this document. This disclaimer needs to be taken into account by those persons which may take a decision over the base of this document or to elaborate or disseminate opinions based hereof. This document may contain summarised information or information that has not been audited. This document is confidential and it cannot be revealed or disclosed to third parties different from the original recipients, even partially, without Virtualware’s prior consent.
Highlights 24 Months of Value Creation
VANCOUVER, British Columbia, Sept. 28, 2026 (GLOBE NEWSWIRE) — Latin Metals Inc. (“Latin Metals” or the “Company“) (TSXV: LMS) (OTCQB: LMSQF) is pleased to announce that holders of the Company’s outstanding common share purchase warrants have exercised 100% of 12,500,000 million warrants at an exercise price of $0.15 per common share, providing $1,875,000 million in proceeds to the Company.
The warrant exercises provide Latin Metals with a meaningful addition to its treasury without undertaking a new equity financing and substantially reduces the Company’s near-term warrant overhang. The additional capital further strengthens Latin Metals’ financial position at a time when significant exploration expenditures across its portfolio are being funded at the project level by strategic partners under the Company’s prospect generator model.
Keith Henderson, President and CEO of Latin Metals, commented:
“The exercise of 100% of this warrant tranche represents a meaningful addition to Latin Metals’ treasury and demonstrates continued shareholder support for the Company. Importantly, this capital is being added at a time when significant exploration expenditures across our portfolio continue to be funded by our partners.
Over the past two years, Latin Metals has significantly expanded the scale of partner-funded exploration and investment across its portfolio, increasing estimated total investment under option agreements from approximately $16 million to $179 million.”
Following the exercise of the September 2026 warrants, the Company will have 151,565,650 common shares issued and outstanding and 12,095,454 warrants remaining outstanding at an exercise price of $0.20.
Latin Metals’ prospect generator strategy is designed to advance a diversified portfolio of copper, gold and silver exploration projects while securing well-funded partners to fund significant exploration expenditures at the project level. This model allows Latin Metals to maintain exposure to multiple potential discoveries while preserving capital and limiting shareholder-funded exploration expenditures.
Partner Investment Growth
Over the past 24 months, Latin Metals has substantially increased the amount of third-party capital and exploration commitments associated with its project portfolio. Between September 2024 and September 2026, total scheduled cash payments under option agreements increased from approximately $2.5 million to $21 million, while aggregate drilling meters under option agreements increased from 15,000 metres to 195,000 metres. Total potential investment under option agreements, including scheduled cash payments and estimated drill expenditures, increased from approximately $16 million to $179 million.
Latin Metals’ market capitalization has grown by approximately 400% over 24 months to September 2026 – from $7 million in September 2024 to $35 million in September 2026.
At the same time, Latin Metals’ expenditures have remained relatively stable on an annual basis.
Figure 1: Comparison of Partner Investment in September 2024, versus September 2026, illustrating significant growth in potential partner investment, and estimated percentage increases in various investment criteria.
This growth reflects the continued execution of Latin Metals’ prospect generator strategy, whereby the Company identifies and advances exploration opportunities before securing well-funded partners to assume a substantial portion of the high-cost exploration risk. The model is intended to expand shareholder exposure to multiple exploration programs while limiting the amount of Latin Metals’ own capital required to fund drilling and other high-cost exploration activities.
Regarding Figure 1 above, the figures presented for scheduled cash payments, drilling commitments and estimated investment under option agreements are based on the terms of the Company’s existing option agreements as at September 2026. To the extent that those figures relate to future periods, they constitute forward-looking information and assume, among other things, that the applicable option agreements remain in effect, the applicable option holders continue to advance those agreements through the relevant stages, scheduled payments are made and contractual drilling commitments are completed.
Actual results may differ materially. In particular, an option holder may elect not to proceed to a subsequent stage; an option agreement may be terminated, amended, surrendered or otherwise not completed; the timing or amount of scheduled payments may change; committed drilling may not be completed; actual drilling costs may differ materially from assumed costs; and the timing or scope of exploration programs may change. Accordingly, some or all of the cash payments, drilling commitments and estimated exploration investment illustrated in Figure 1 may not be received, completed or incurred, and the figures should not be interpreted as a forecast of amounts the Company expects to receive or expenditures that will necessarily be incurred.
Estimated investment attributable to drilling is based on assumed all-in drilling costs of approximately US$500 to US$700 per meter, depending on the project, based on costs observed at comparable projects, and actual costs may differ materially. Incoming cash payments include amounts paid or potentially payable directly to Latin Metals and, in certain cases, amounts paid or potentially payable under underlying option agreements. Total potential investment excludes discretionary top-up, buy-out and royalty buy-back payments. Latin Metals’ expenditures may vary depending on the number, timing, cost and scope of future acquisitions and exploration programs. Market capitalization figures are approximate point-in-time estimates and are not based on VWAP.
Correction to June 29, 2026 News Release
The Company wishes to correct its news release dated June 29, 2026 regarding the grant of 400,000 stock options. The news release incorrectly stated that the options were granted to certain directors, officers and consultants of the Company. The options were granted solely to consultants of the Company, and no options were granted to any directors or officers. All other terms of the option grant remain unchanged.
About Latin Metals
Latin Metals Inc. is a copper, gold and silver exploration company operating in Peru and Argentina under a prospect generator model, minimizing risk and dilution while maximizing discovery potential. The company secures option agreements with partners to fund exploration. This approach provides early-stage exposure to high-value mineral assets. Latin Metals is actively seeking new strategic partners to advance its portfolio.
Stay Connected
Follow Latin Metals on YouTube, X, Facebook, LinkedIn and Instagram to stay informed on our latest developments, exploration updates, and corporate news.
Upcoming Events
Latin Metals is pleased to announce its participation in several industry conferences, providing a platform to connect with investors, industry leaders, and potential partners:
- New Orleans Investment Conference – New Orleans, Louisiana, USA, October 28-31, 2026
- 121 London – London, UK, November 23-24, 2026
These events offer valuable opportunities to share Latin Metals’ exploration progress in Argentina and Peru, highlight the advantages of its low-dilution prospect generator model, and explore strategic investment and partnership opportunities across its gold, copper, and silver-focused portfolio.
Qualified Person
Eduardo Leon, QP, is the Company’s qualified person as defined by NI 43-101 and has reviewed the scientific and technical information that forms the basis for portions of this news release. He has approved the disclosure herein. Mr. Leon is not independent of the Company, as he is an employee of the Company and holds securities of the Company.
On Behalf of the Board of Directors of
LATIN METALS INC.
“Keith Henderson“
President & CEO
For further details on the Company, readers are referred to the Company’s website (www.latin-metals.com) and its Canadian regulatory filings on SEDAR+ at www.sedarplus.com.
For further information, please contact:
Keith Henderson
Suite 1920 – 1188 Georgia Street,
Vancouver, BC, V6E 4A2
Elyssia Patterson, VP Investor Relations
Email: elyssia@latin-metals.com
Phone: 778-683-4324
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this news release.
Cautionary Note Regarding Forward-Looking Statements
This news release contains forward-looking statements and forward-looking information (collectively, “forward-looking statements”) within the meaning of applicable Canadian and U.S. securities laws. All statements other than statements of historical fact may constitute forward-looking statements, including statements regarding anticipated exploration activities and results; the timing, scope and cost of exploration programs; the Company’s ability to acquire additional mineral properties and enter into option, earn-in or other agreements with exploration partners; scheduled or potential cash payments, drilling commitments and exploration expenditures under existing option agreements; estimated drilling costs and aggregate potential partner investment; the continuation and performance of option agreements; and the Company’s anticipated business plans and future activities.
Forward-looking statements are based on management’s current expectations, estimates, assumptions and projections as of the date of this news release. Material assumptions include, where applicable, that existing option agreements remain in effect, that option holders elect to continue to advance those agreements through the applicable stages, that scheduled payments and exploration commitments are made or completed, that exploration programs proceed substantially as presently contemplated, that assumed drilling costs are reasonable, that required permits and approvals are obtained when required, and that the Company and its exploration partners have access to sufficient financing and other resources to carry out their respective activities.
Forward-looking statements are subject to known and unknown risks, uncertainties and other factors that may cause actual results, activities or events to differ materially from those expressed or implied by such statements. These risks include, among others, the risk that an option holder may elect not to proceed to a subsequent stage of an option agreement; that an option agreement may be terminated, amended, surrendered or otherwise not completed; that the timing or amount of scheduled payments may change; that committed drilling or other exploration activities may not be completed; that actual drilling and exploration costs may differ materially from estimates; that the timing, scope or results of exploration programs may change; that permits or regulatory approvals may be delayed or not obtained; changes in commodity prices, financial markets and economic conditions; availability of financing; title and permitting risks; environmental and social risks; political and regulatory risks in the jurisdictions in which the Company operates; and the other risks described under “Risk Factors” in the Company’s most recently filed management’s discussion and analysis and other continuous disclosure documents available under the Company’s profile on SEDAR+.
Although the Company believes that the expectations and assumptions reflected in such forward-looking statements are reasonable, there can be no assurance that they will prove to be correct. Readers are cautioned not to place undue reliance on forward-looking statements. Except as required by applicable securities laws, the Company undertakes no obligation to update or revise any forward-looking statements as a result of new information, future events or otherwise.
A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/2f5c057d-0794-4df0-bd89-abe3224a22b0
NOT FOR DISTRIBUTION IN THE UNITED STATES. FAILURE TO COMPLY WITH THIS RESTRICTION MAY CONSTITUTE A VIOLATION OF UNITED STATES SECURITIES LAW
CALGARY, Alberta, Sept. 28, 2026 (GLOBE NEWSWIRE) — Unless otherwise stated, all numbers in this press release are presented in Canadian dollars. Alaris Equity Partners Income Trust (“Alaris” or the “Trust“) (TSX: AD.UN) is pleased to announce the closing of the previously announced public offering (the “Offering“) of trust units of the Trust (“Units“) through a syndicate of underwriters (the “Underwriters“) led by CIBC Capital Markets, Acumen Capital Finance Partners Limited and National Bank of Canada Capital Markets and including Raymond James Ltd., Desjardins Capital Markets, RBC Capital Markets, ATB Capital Markets Corp., and Canaccord Genuity Corp., on a bought-deal basis. A total of 5,134,750 Units were issued in connection with the Offering at a price of $22.40 per Unit for aggregate gross proceeds of $115,018,400, which includes Units issued on the exercise in full of the over-allotment option granted to the Underwriters in connection with the Offering to purchase 669,750 Units.
The Trust intends to use the net proceeds of the Offering to partially repay outstanding indebtedness under its senior credit facility, which may be subsequently redrawn and used to fund future investments in new Partners (as defined below) and for general trust purposes.
ABOUT ALARIS
Alaris’ investment and investing activity refers to providing, through the wholly-owned subsidiaries of Alaris (the “Acquisition Entities“), structured equity to private companies (“Partners“) to meet their business and capital objectives, which includes management buyouts, dividend recapitalization, growth and acquisitions. Alaris achieves this by investing its unitholder capital, as well as debt, through the Acquisition Entities, in exchange for distributions, dividends or interest (collectively, “Distributions“) as well as capital appreciation on both preferred and common equity. The principal objective is to generate predictable cash flows for distribution payments to its unitholders while growing net book value through returns from capital appreciation. Distributions, other than common equity Distributions, from the Partners are adjusted annually based on the percentage change of a “top-line” financial performance measure such as gross margin or same store sales and rank in priority to common equity position.
This news release is not an offer of securities of Alaris for sale in the United States. The Units have not been and will not be registered under the U.S. Securities Act of 1933, as amended, and the Units may not be offered or sold in the United States except pursuant to an applicable exemption from such registration. No public offering of securities is being made in the United States. This news release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the securities in any jurisdiction in which such offer, solicitation or sale would be unlawful.
FORWARD LOOKING STATEMENTS
This press release contains certain forward-looking information and statements within the meaning of applicable securities laws. The use of any of the words “expect”, “anticipate”, “continue”, “estimate”, “may”, “will”, “project”, “should”, “believe”, “plans”, “intends” and similar expressions are intended to identify forward-looking information or statements. In particular, but without limiting the foregoing, this press release contains forward-looking statements concerning the intended use of the net proceeds of the Offering. Although Alaris believes that the expectations reflected in these forward-looking statements are reasonable, undue reliance should not be placed on them because Alaris can give no assurance that they will prove to be correct. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. The forward-looking statements contained in this press release are made as of the date hereof and Alaris undertakes no obligation to update publicly or revise any forward-looking statements or information, whether as a result of new information, future events or otherwise, unless so required by applicable securities laws.
For further information please contact:
ir@alarisequity.com
P: (403) 260-1457
Alaris Equity Partners Income Trust
Suite 250, 333 24th Avenue S.W.
Calgary, Alberta T2S 3E6
www.alarisequitypartners.com
New U.S. patent expands intellectual property foundation for DARE-HPV, a potential first-in-category treatment targeting persistent high-risk HPV infection
DARE-HPV Phase 2 study underway with topline results expected in 2027; program supported by approximately $10 million in non-dilutive ARPA-H funding and a $2.0 million NIAID award
DARE-HPV is designed to address a major treatment gap for the millions of U.S. women who experience high-risk HPV infection each year, for which there is currently no FDA-approved pharmacologic treatment
SAN DIEGO, Sept. 28, 2026 (GLOBE NEWSWIRE) — Daré Bioscience, Inc. (NASDAQ: DARE), a purpose-driven health biotech company solely focused on closing the gap in women’s health between promising science and real-world solutions, today announced the issuance of U.S. Patent No. 12,678,439, titled “Lopinavir and Ritonavir for the Treatment of Cervix Disorders,” which covers pharmaceutical compositions formulated for topical application comprising lopinavir and ritonavir for the treatment of HPV-related cervical pathologies.
The patent, issued by the United States Patent and Trademark Office on July 14, 2026, to Douglas Pharmaceuticals Limited, a licensor to Daré Bioscience, describes pharmaceutical compositions containing therapeutically effective amounts of lopinavir and ritonavir, including specific lopinavir-to-ritonavir weight ratios and formulations designed for topical administration. The patent includes claims directed to compositions for treating or inhibiting the development of early-stage neoplasias and for treating or preventing HPV-related cervical neoplasias. The patent is expected to provide protection into at least 2039.
“This patent adds another important layer to the foundation we are building around DARE-HPV at a particularly exciting point in the program’s development,” said Sabrina Martucci Johnson, President and CEO of Daré Bioscience. “Millions of women experience high-risk HPV infection each year in the United States, yet there is still no FDA-approved pharmacologic treatment to clear the infection. DARE-HPV is designed to change that paradigm with a localized, self-administered, non-surgical approach, and our Phase 2 study is now evaluating its potential to do exactly that. With clinical development underway, significant non-dilutive funding supporting the program, and an expanded intellectual property position, we believe DARE-HPV represents a compelling opportunity to address a significant unmet need in women’s health and, if successful and approved, potentially establishing the first FDA-approved pharmacologic treatment for HPV infection.”
The patent adds to the intellectual property landscape supporting the development of DARE-HPV, Daré Bioscience’s investigational proprietary fixed-dose formulation of lopinavir and ritonavir in a soft gel vaginal insert being developed as a potential treatment for persistent high-risk human papillomavirus (HPV) infection. Daré holds an exclusive U.S. license to the patent described above and the broader patent family related to DARE-HPV under its 2023 license agreement with Douglas Pharmaceuticals Limited.
DARE-HPV is currently being evaluated in a Phase 2 randomized, placebo-controlled, double-blind clinical study in approximately 100 women with confirmed persistent high-risk HPV infection (ClinicalTrials.gov ID: NCT07601074). The study is designed to evaluate the safety and antiviral activity of lower and higher doses of DARE-HPV compared with placebo over an up to 21-day course of daily treatment, with HPV clearance at three months post-treatment as the primary endpoint. Topline results are expected in 2027.
DARE-HPV is being developed as a non-surgical, localized, self-administered therapy designed to clear persistent high-risk HPV infection. There are currently no FDA-approved pharmacologic treatments for HPV infection. Daré Bioscience’s development of DARE-HPV is supported by approximately $10 million in non-dilutive funding from the Advanced Research Projects Agency for Health (ARPA-H) as Sprint for Women’s Health awardee, and a $2.0 million award granted by the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (Award Number R44AI188623).
ABOUT DARE-HPV
DARE-HPV is an investigational, proprietary fixed-dose formulation of lopinavir and ritonavir in a soft gel vaginal insert being developed as a potential non-surgical, localized, self-administered treatment for persistent high-risk HPV infection. Lopinavir and ritonavir are protease inhibitors with established antiviral activity. HPV infection is the underlying cause of virtually all cervical cancer cases in the United States. An estimated six million women per year in the United States experience high-risk HPV infection, for which there are currently no FDA-approved pharmacologic treatments. If clinically successful and approved, DARE-HPV could be the first FDA-approved pharmacologic treatment for HPV infection.
ABOUT DARÉ BIOSCIENCE, INC.
Daré Bioscience (NASDAQ: DARE) is a purpose-driven health biotech company solely focused on closing the gap in women’s health between promising science and real-world solutions. Every innovation Daré Bioscience advances is based in advanced science and backed by rigorous, peer-reviewed research. From contraception to menopause, sexual health to fertility, vaginal health to infectious disease, Daré Bioscience is working to close critical gaps in care using science that serves her needs. For decades, women have been told to “wait it out” or “live with it,” while innovations that could improve their quality of life languish in the regulatory or funding pipeline. With growing awareness around menopause, sexual health, and vaginal health, the conversation is shifting. However, access to proven solutions is lagging. Daré Bioscience is working to change that. Learn more at darebioscience.com.
FORWARD-LOOKING STATEMENTS
Daré Bioscience cautions you that all statements, other than statements of historical facts, contained in this press release, are forward-looking statements. Forward-looking statements, in some cases, can be identified by terms such as “believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” “design,” “intend,” “expect,” “could,” “plan,” “potential,” “prepare,” “progress,” “seek,” “should,” “would,” “build” or the negative version of these words and similar expressions.
In this press release, forward-looking statements include, but are not limited to, statements relating to: DARE-HPV’s potential as a safe and effective treatment for clearance of high-risk HPV infection; DARE-HPV’s potential to be a first-in-category treatment targeting persistent high-risk HPV infection and to be the first FDA-approved pharmacologic treatment for high-risk HPV infection; the conduct and completion of the Phase 2 clinical study of DARE-HPV and the timing of topline data from the study; the anticipated benefits of DARE-HPV, including its potential to reduce the incidence of cervical cancer in the U.S.; the potential for DARE-HPV to redefine the treatment paradigm in cervical disease prevention; the expected duration of patent protection into at least 2039; Daré Bioscience’s expectation of receipt of additional funding under its ARPA-H award and NIAID award; and the potential market opportunity for DARE-HPV, if approved. As used in this press release, “first-in-category” is a forward-looking statement relating to the potential of a product candidate to represent a new category of product if it were to receive marketing approval for the indication for which it is being developed because Daré Bioscience believes it would address a need in women’s health that is not being met by existing FDA-approved products.
Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause Daré Bioscience’s actual results, performance or achievements to be materially different from future results, performance or achievements expressed or implied by the forward-looking statements in this press release, including, without limitation, risks and uncertainties related to: failure or delay in conducting or completing clinical trials and the inherent uncertainty of outcomes of clinical trials; the risk that positive findings in early clinical and/or nonclinical studies of a product candidate may not be predictive of success in subsequent clinical and/or nonclinical studies of that candidate; Daré Bioscience’s ability to develop, obtain FDA or foreign regulatory approval for, and commercialize its product candidates and to do so on communicated timelines; the risk that Daré Bioscience’s product candidates may fail to demonstrate acceptable safety and tolerability or sufficient efficacy in clinical trials; Daré Bioscience’s ability to design and conduct successful clinical trials, to enroll a sufficient number of patients, to meet established clinical endpoints, to avoid undesirable side effects and other safety concerns, and to demonstrate sufficient safety and efficacy of its product candidates; Daré Bioscience’s dependence on third parties to conduct clinical trials and manufacture and supply clinical trial material and commercial product; the potential that a product candidate in clinical development may never advance into or through a pivotal clinical study or obtain FDA or foreign regulatory approval; the risk that the FDA, other regulatory authorities, members of the scientific or medical communities or investors may not accept or agree with Daré Bioscience’s interpretation of or conclusions regarding data from clinical studies of its product candidates; the risk that development of a product candidate requires more clinical or nonclinical studies than Daré Bioscience anticipates, or that the duration of a study or number of study subjects must be significantly greater than anticipated; Daré Bioscience’s ability to achieve the milestones required for it to receive additional payments under its ARPA-H award and NIAID award; Daré Bioscience’s dependence on grants and other financial awards from governmental entities and the risk that funding may be reduced, delayed, or terminated; Daré Bioscience’s ability to raise additional capital when and as needed to execute its business strategy and continue as a going concern; Daré Bioscience’s ability to maintain compliance with Nasdaq’s continued listing requirements and continue to have its common stock listed on The Nasdaq Capital Market; the effects of macroeconomic conditions, geopolitical events, and major changes and disruptions in U.S. government policies and operations on Daré Bioscience’s ability to raise additional capital or on Daré Bioscience’s operations, financial results and condition, and ability to achieve current plans and objectives; the risk that the intellectual property landscape supporting DARE-HPV, including the newly issued patent and the licensed patent family, may not provide the expected scope or duration of protection, and the risk that patent protection may not extend into 2039 as currently expected; the risk that the current regulatory pathway known as the FDA’s 505(b)(2) pathway for drug product approval in the U.S. is not available for a product candidate as Daré Bioscience anticipates; the risk that developments by competitors make Daré Bioscience’s product or product candidates less competitive or obsolete; difficulties establishing and sustaining relationships with development and/or commercial collaborators; failure of Daré Bioscience’s products or product candidates, if approved, to gain market acceptance or obtain adequate coverage, pricing and reimbursement from third-party payors; Daré Bioscience’s ability to retain its licensed rights to develop and commercialize a product or product candidate; Daré Bioscience’s ability to satisfy the monetary obligations and other requirements in connection with its exclusive, in-license agreements covering the critical patents and related intellectual property related to its products and product candidates; Daré Bioscience’s ability to adequately protect or enforce its, or its licensor’s, intellectual property rights; the lack of patent protection for the active ingredients in certain of Daré Bioscience’s product candidates, which could expose its products to competition from other formulations using the same active ingredients; product liability claims; governmental investigations or actions relating to Daré Bioscience’s products or product candidates or the business activities of Daré Bioscience, its commercial collaborators or other third parties on which Daré Bioscience relies; the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; and cybersecurity incidents or similar events that compromise Daré Bioscience’s technology systems and/or significantly disrupt Daré Bioscience’s business or those of third parties on which Daré Bioscience relies.
Daré Bioscience’s forward-looking statements are based upon its current expectations and involve assumptions that may never materialize or may prove to be incorrect. All forward-looking statements are expressly qualified in their entirety by these cautionary statements. For a detailed description of Daré Bioscience’s risks and uncertainties, you are encouraged to review its documents filed with the U.S. Securities and Exchange Commission (SEC), including Daré Bioscience’s recent filings on Form 8-K, Form 10-K and Form 10-Q. You are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date on which they were made. Daré Bioscience undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as required by law.
Contact:
Daré Bioscience Investor Relations
innovations@darebioscience.com
Source: Daré Bioscience, Inc.
Borregaard has today entered into three bilateral multicurrency revolving credit facility agreements with Danske Bank, DNB Bank ASA, and Skandinaviska Enskilda Banken, respectively. The facilities, which are linked to sustainability targets, amount in total to NOK 1,500 million, with each bank providing NOK 500 million.
The margin under the respective facilities can be adjusted based on Borregaard’s progress on three parameters: (i) the Group’s target of reducing greenhouse gas emissions (Scope 1 and 2), (ii) reduction of the Group’s total recordable injuries and (iii) reduced emissions of organic compounds to the Glomma river.
The facilities have tenors of five years with two one-year extension options. The new facilities are for general corporate purposes and replace the NOK 1,500 million revolving credit facilities with maturity in 2027.
Skandinaviska Enskilda Banken acted as documentation coordinator for the facilities.
Borregaard ASA,
Sarpsborg, 28 September 2026
Contact:
Group Treasurer and IR, Magnus Hammerstad, +47 959 04 640
This information is subject to the disclosure requirements pursuant to Section 5 -12 of the Norwegian Securities Trading Act and requirements under the EU Market Abuse Regulation.
Former Division I football player Michael Lowe is gaining hands-on network engineering experience with the San Francisco 49ers, applying skills from Cisco Networking Academy in one of the most connected environments in sports.
As a Division I football player at UC Berkeley, Michael Lowe once stepped onto Levi’s® Stadium’s field under the bright lights of game day. This summer, he returned to the stadium in a very different role, working behind the scenes as a Cisco Networking Academy Apprentice alongside the San Francisco 49ers Network Engineering team.
Lowe knows what it’s like to compete and lead on the field from his time as UC Berkeley football captain. Now he’s seeing the game from an entirely different perspective—inside the IT operations that support one of the NFL’s most technology-driven organizations.
Fans experience every touchdown, replay, announcement, concession purchase, and media interaction seamlessly, thanks to complex network infrastructure operating behind the scenes. During the apprenticeship, Lowe is gaining first-person, hands-on learning experience with the technology systems that support game day operations across the stadium as the 49ers host high-profile events and international sporting matches and prepare for the 2026-2027 NFL season.
Earlier this year, Lowe participated in the Cisco Networking Academy Dream Team at Cisco Live, where he built relationships and shared his goal of combining his sports background with his new career in network engineering. Those conversations ultimately helped open the door to the 49ers apprenticeship.
I spoke with Lowe about the experience, the lessons he’s learned, and how Cisco Networking Academy helped launch his journey into network engineering.
From the gridiron to the server room
Hayley: You played college football yourself. You’re a D1 athlete. How does that background give meaning to this opportunity? It’s almost like you’ve made it to the big leagues in a way. How has your experience as an athlete shaped this experience on the other side?
Michael: My experience as an athlete has pretty much shaped my entire professional career. I went to Berkeley, which is right down the road. I actually had an opportunity to play in this stadium when I was in college. We played Oregon here in 2014.
So now, walking into it on this side of things, it’s surreal to be able to look at it from behind the scenes—not on the field, but inside a technical office—and really see how all the departments work together and how IT is responsible for making sure the connectivity is there, the security is there, and everybody has access to what they need.
I’ve walked into this situation with that same mindset. Even when it comes to learning network engineering, I take the football approach.
In network engineering, you have a lot of different terms. You have IPv4, IPv6, STP, RSTP—different protocols. The way I break them down is just like a football playbook. We have different packages: 4-3, 3-4, dime, nickel. Some of those terms may not ring a bell, but we have all these different packages, and within those packages we have different plays, different terminology that we have to understand and memorize.
I take that same approach into technology and network engineering. We have different protocols, and those protocols are responsible for different things and have different terminology. But overall, it’s all about security, connectivity, and having access.
What fans don’t see on game day
Hayley: You’ve been on the field. What’s something that’s surprised you about what goes on behind the scenes to make everything run at a stadium?
Michael: Just seeing how IT is involved in configuring all of the devices and technology that each department uses.
Whether it be the TVs around the stadium that fans see when they go to the concession stands, having the menu items on the televisions—those are areas IT is responsible for.
The same goes for press box devices. When you have different media groups in the press boxes and in their offices, they need access and connectivity. Even the stadium microphone system works underneath the IT department. So it is pretty cool to see how hands-on we are, but also to see how all of those things work together. When you hear your name being called after making a play, it’s good to know that the IT team is making sure those things are working for everybody.
Finding a path through Cisco Networking Academy
Hayley: How did you first get started with Cisco Networking Academy?
Michael: I’m from Washington, D.C., originally. In D.C., we have a D.C. Infrastructure Academy. I decided to go into CCNA network engineering, so I joined that program. Through that program, I really excelled. Again, I took that approach from football and walked into the classroom ready to break down those terms, get a better understanding of network engineering, ask questions, learn, and not be afraid to make mistakes and learn from them.
My instructor, Tabitha, was great. I give her a lot of credit for helping me understand what network engineering is. I had no background in IT. My degree is in legal studies, so it was really a career switch for me.
Through that, I was nominated to go to Cisco Live.
Behind the scenes at Cisco Live
Hayley: What was your experience as part of the Cisco Networking Academy Dream Team at Cisco Live like, and how did it help set you up for this role?
Michael: At Cisco Live, we did a lot of physical deployment—not so much technical work—but we got to see the blueprints and talk to Cisco industry leaders about how these events are planned months in advance.
We learned about all the different things that need to be in place for events like these to be successful. Learning what goes into it on the back end was extremely cool.
You think you just walk into a situation and start setting things up, but it’s actually a lot of planning and blueprinting. It was pretty cool to ask questions and talk to different people about that.
Also, seeing some of the vendors and how they interact with Cisco, and how those relationships are built between vendors and Cisco themselves, was valuable.
Being with that team and that group of people really opened my eyes. I have a very “it needs to get done” approach, and I might create some anxiety around myself because of it. But seeing how patient everyone was, how things were planned out, and how much self-control they had in that environment really opened my eyes.
It helped me see that you can trust your planning and trust your strategy. Things will get done. You don’t have to create a false sense of urgency.
Leadership beyond the field
Hayley: At Berkeley, you were part of the Big C Society, recognizing leadership on and off the field—how has that shaped the way you approach teamwork and leadership in your career today?
Michael: Yeah, and I’m glad you brought that up because, being completely transparent, early in my collegiate career I stumbled a lot. I had to get used to it.
After my sophomore year, I took it upon myself to lead by example. Don’t be the guy who’s vocal but not putting in the work. I’d rather be the guy who’s quiet and just putting in the work. Through that process, all the way up to my senior year, I was recognized by my teammates and voted team captain.
I was able to increase my academic standards, improve my work ethic on the field and in the weight room, and eventually become a vocal leader for the guys. After they saw me lead by example, it opened up my confidence to become more vocal.
Being a part of the Big C Society, I embodied accountability, leadership, and responsibility on and off the field. To be recognized by a group like that was an honor, and I was extremely thankful for it.
Skills and opportunity can open doors
Hayley: How do you see these experiences shaping what’s next for you in your career?
Michael: I look at it as a testimony—a story I’ll be able to look back on and say that, as a new student entering a new career in a very broad field, experiences like Dream Team have really given me the motivation and confidence to tell myself that I can do this.
They’ve also given me the opportunity to really learn—to be a sponge in these environments, take all the notes you can, ask all the questions you can, and make all the connections you can because these are once-in-a-lifetime opportunities.
Being able to talk to different people along their career paths and hear where they started, and how opportunities came from the things they believed in and worked for—as well as from the people who helped them along the way—is incredibly valuable.
Taking this experience and using it as a catapult into the next experience is what I’m hoping to do. I want to learn everything I can while I’m here, so I’m prepared for whatever comes next.
For Lowe, the apprenticeship is more than a summer experience. It’s a testament to how the right combination of skills, mentorship, and opportunity can open doors to meaningful careers. Through Cisco Networking Academy, students gain the technical knowledge, confidence, and industry connections needed to take the next step in their professional journey. From the CCNA classroom to Cisco Live to an NFL stadium, Lowe’s story demonstrates how hands-on learning experiences can help learners turn ambition into opportunity and launch careers in technology.
View original content here.
Enters into a non-binding term sheet which will potentially provide control over two data center development projects in Warsaw and Wroclaw, Poland, with planned capacity of up to 270 MW
NESS ZIONA, Israel, Sept. 28, 2026 (GLOBE NEWSWIRE) — Foresight Autonomous Holdings Ltd. (Nasdaq and TASE: FRSX) (“Foresight” or the “Company”), an innovator in 3D perception systems, announced today that it has entered into a non-binding term sheet for the proposed acquisition of a 50.01% controlling interest in a company advancing data center development projects in Poland (the “Data Centers Company”).
The Data Centers Company is expected to hold a 66.67% interest in each of two Polish project companies developing data centers in Warsaw and Wroclaw, two of the biggest and growing cities in Poland. The Warsaw project has a planned power capacity of 130 MW, while the Wroclaw project has a planned capacity of up to 140 MW, representing combined planned capacity of up to 270 MW.
The remaining 33.33% interest in both projects will be held by Polish development entrepreneurs who are engineering experts leading national grid connection processes, techno-economic analysis and regulatory matters and lead the securing of grid connection terms for projects totaling several gigawatts.
The Warsaw project, located in Ożarów, Poland, includes approximately 3.2 hectares of secured land, with an additional 2.2-hectare option. A grid connection application has been submitted, with final permit currently expected by the end of 2027. The Wroclaw project encompasses approximately 10 hectares, with its feasibility study completed and land currently under negotiation.
According to the data produced by the European Data Centre Association , Poland’s colocation capacity is forecast to increase from approximately 29 MW in 2026 to 511 MW by 2031, underscoring the country’s position as a growing data center market in the Central and Eastern Europe.
Haim Siboni, Chief Executive Officer of Foresight, said, “As we previously announced, Foresight has been evaluating opportunities to expand into new technology markets and identify additional areas for growth beyond our existing activities, including data centers. The proposed transaction is a natural extension of this strategy, providing Foresight with an opportunity to establish a controlling interest in a platform advancing two data center projects in Poland. At the same time, we continue to advance our proprietary technologies and expand their applications, including our recently announced development of full autonomous driving solutions for Unmanned Ground and Aerial Vehicles.”
The purchase price for the 50.01% interest in the Data Centers Company will be determined based on an independent valuation to be prepared by a mutually agreed independent valuation firm prior to execution of definitive agreements. The consideration would be financed in full through a seller loan.
At closing, Foresight expects to also contribute an amount currently estimated at approximately $1 million, representing its pro rata share of the Data Centers Company’s outstanding shareholder loans, and would commit to provide additional shareholder loans of up to $2.5 million to advance the two projects. To fund these obligations, the Data Centers Company current shareholders, or anyone on their behalf, shall provide Foresight with a convertible loan facility, from time to time, of up to US$3,500,000, all subject to an agreed budget, business plan and projects milestones, with terms to be agreed upon a separate agreement.
The proposed transaction remains subject to the completion of Foresight’s due diligence, an independent valuation, agreement on definitive transaction documents and transaction structure, and receipt of required corporate, regulatory, stock exchange, governmental, financing, and third-party approvals.
Eli Yoresh, the Company’s Chief Financial Officer, owns a 10% stake in the Data Centers Company.
About Foresight
Foresight Autonomous Holdings Ltd. (Nasdaq and TASE: FRSX) is a technology company developing advanced three-dimensional (3D) perception systems and cellular-based applications. Through its wholly owned subsidiaries, Foresight Automotive Ltd., Foresight Changzhou Automotive Ltd., and Eye-Net Mobile Ltd., Foresight develops both “in-line-of-sight” vision systems and “beyond-line-of-sight” accident-prevention solutions.
Foresight’s 3D perception systems include modules of automatic calibration and dense 3D point cloud that can be applied to different markets such as automotive, defense, autonomous driving, agriculture, heavy industrial equipment, and unmanned aerial vehicles (UAVs).
Eye-Net Mobile develops next-generation vehicle-to-everything collision prevention solutions and smart automotive systems to enhance road safety and situational awareness for all road users in urban mobility environments. By leveraging cutting-edge artificial intelligence technology, advanced analytics, and existing cellular networks, Eye-Net’s innovative solution suite delivers real-time pre-collision alerts to all road users via smartphones and other smart devices within vehicles.
For more information about Foresight and its wholly owned subsidiary, Foresight Automotive, visit www.foresightauto.com, follow @ForesightAuto1 on X, or join Foresight Automotive on LinkedIn.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995 and other Federal securities laws. Words such as “expects,” “anticipates,” “intends,” “plans,” “believes,” “seeks,” “estimates” and similar expressions or variations of such words are intended to identify forward-looking statements. For example, Foresight is using forward-looking statements in this press release when it discusses the likelihood of success of data center development in Poland, possible growth in the European energy market, the likelihood of energy production by the potential data centers, entry into definitive agreements and future cooperation between the parties to the nonbinding term sheet and that the proposed transaction remains subject to the completion of Foresight’s due diligence, an independent valuation, agreement on definitive transaction documents and transaction structure, and receipt of required corporate, regulatory, stock exchange, governmental, financing, and third-party approvals. Because such statements deal with future events and are based on Foresight’s current expectations, they are subject to various risks and uncertainties, and actual results, performance or achievements of Foresight could differ materially from those described in or implied by the statements in this press release.
The forward-looking statements contained or implied in this press release are subject to other risks and uncertainties, including those discussed under the heading “Risk Factors” in Foresight’s annual report on Form 20-F for the fiscal year ended December 31, 2025, filed with the Securities and Exchange Commission (“SEC”) on March 25, 2026, and in any subsequent filings with the SEC. Except as otherwise required by law, Foresight undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. References and links to websites have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release. Foresight is not responsible for the content of third party websites.
Investor Relations Contact:
Miri Segal-Scharia
CEO
MS-IR LLC
msegal@ms-ir.com
